Azerion successfully places EUR 165 million of senior secured floating rate bonds
NOT FOR DISTRIBUTION TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OFAMERICA OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S UNDER THE U.S.SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT")) OR IN ANY OTHERJURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS DOCUMENT.
Azerion successfully places EUR 165 million of senior secured floating rate bonds
Amsterdam, 14 September 2023 – Azerion Group N.V. (the “Company”) has, following a bookbuilding process, successfully placed EUR 165 million of senior secured floating rate bonds under a framework of EUR 300 million to qualified institutional investors internationally (the “New Bonds”). The New Bonds will have a 3-year tenor, will carry a floating rate coupon of 3 months EURIBOR plus 6.75 per cent per annum and were issued at 98.5 per cent of par.
Proceeds from the New Bonds in combination with current cash holdings of the Company will be used to fully redeem the Company’s outstanding EUR 200 million senior secured fixed rate bonds (ISIN SE0015837794) (the “Existing Bonds”) and to finance general corporate purposes of the Company, including capital expenditure and transaction costs.
Ben Davey, CFO Azerion:
“We are delighted with the successful placement of the New Bonds and the strong support we have received from existing and new bond investors across the Nordics, Europe and the U.S. Achievingthis target milestone strengthens our balance sheet and at the same time supports our continued focuson growing our Platform and the execution of our consolidation and integration strategy.”
Notice of redemption of the Existing Bonds is expected to be sent to bondholders on 15 September 2023 for redemption on 30 October 2023 at a price of 100.725 per cent of the nominal amount plus accrued unpaid interest in accordance with the terms and conditions of the Existing Bonds.
Settlement of the New Bonds is expected to take place on 2 October 2023 (the "First Issue Date"). The Company shall use its best efforts to ensure that the New Bonds will be listed on a Regulated Market within 60 days (with an intention to complete such listing within 30 days) and on Frankfurt Stock Exchange Open Market as soon as practically possible after the First Issue Date.
Pareto Securities AB acted as Sole Bookrunner and Roschier Advokatbyrå acted as legal advisor in connection with the bond issue.
Founded in 2014, Azerion (EURONEXT: AZRN) is one of Europe’s largest digital advertising and entertainment media platforms. We bring global scaled audiences to advertisers in an easy and cost-effective way, delivered through our proprietary technology, in a safe, engaging, and high quality environment, utilizing our strategic portfolio of owned and operated content with entertainment and other digital publishing partners. Having its roots in Europe and with its headquarters in Amsterdam, Azerion has commercial teams based in over 26 cities around the world to closely support our clients and partners to find and execute creative ways to make a real impact through advertising.
For more information visit: www.azerion.com
Head of Investor Relations
This press release relates to the disclosure of information that qualified, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
This communication does not constitute an offer to sell, or a solicitation of an offer to buy, any securities or any other financial instruments.
This communication does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any New Bonds or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with or act as an inducement to enter into, any contract or commitment whatsoever.
In particular, this communication does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, or form part of any offer, invitation or solicitation to purchase, securities to any person located or resident in the United States or to any U.S. Person (as defined in Regulation S under the U.S. Securities Act). The securities referred to herein have not been, and will not be, registered pursuant to U.S. Securities Act or any securities laws in any state or other jurisdiction in the United Sates and may not be offered, sold, accepted, exercised, re-sold, renounced, transferred or delivered, whether directly or indirectly, in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. No public offering of securities is being, has been, or will be made in the United States.
This communication is made accessible on the basis that any offers of securities referred to herein in any Member State of the EEA will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of such securities. The New Bonds have, with respect to persons in Member States of EEA, only been offered to persons who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation and Section 1:1 of the Dutch Financial Supervision Act. The expression "Prospectus Regulation" means Regulation No. 1129/2017.
In the United Kingdom, the material is made accessible on the basis that any offers of securities referred to herein will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of such securities. The New Bonds have, with respect to persons in the United Kingdom, only been offered to persons who are qualified investors within the meaning of Article 2(1)(e) of the UK Prospectus Regulation. The expression “UK Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of retained EU law as defined in the EU (Withdrawal) Act 2018.
The release, publication or distribution of the material may be restricted by law and persons in such jurisdictions in which a release, publication or distribution of the material should therefore inform themselves about, and observe, any such restrictions.
This press release may include projections and other "forward-looking" statements within the meaning of applicable securities laws. Any such projections or statements reflect the current views of the Company about future events and financial performance. No assurances can be given that such events or performance will occur as projected and actual results may differ materially from these projections.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration3.10.2023 22:05:00 CEST | Press release
PHAXIAM Therapeutics and Vetophage Announce Strategic ResearchCollaboration Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy Combining expertise in the research of new phages and phage endolysins that could be applied to human health Exclusive phage and endolysin licensing options in human health for PHAXIAM Therapeutics Lyon (France) and Cambridge (MA, US), October03, 2023 – 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) and Vetophage, a company specialized in phage therapy applied to animal health, announce the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance. Vetophage is a Lyon-based biotechnology company founded in 2017. It develops new tools to detect pathogenic bacteria and alternative solutions to antibiotics based on phages an
Kvika banki hf.: TM Insurance to be sold or listed3.10.2023 21:05:43 CEST | Press release
Following a strategic review at Kvika banki hf. ("Kvika" or "the bank"), the board of directors of Kvika has decided to initiate a process for the sale or listing of its insurance subsidiary TM tryggingar hf. ("TM"). The decision is in line with the bank's vision, where emphasis is placed on simplifying the group's operations and strengthening Kvika's traditional banking activities, in accordance with the bank's goal to increase competition and simplify its customers' finances. Following the divestment of TM, Kvika's main operations will be focused on commercial- and investment banking, along with asset management. It is expected that Kvika's capital base will grow significantly following the divestment of TM, enabling the bank to pursue internal growth opportunities across Kvika's business segments. Increased capital will, among other things, enable the bank to strengthen its market position, in both retail and corporate lending, and increase the risk diversification of its loan book.
Policane® Natural Sweetener Found to Have Low Glycemic Index3.10.2023 20:06:38 CEST | Press release
OCALA, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Policane®, a natural sweetener made from sugar cane juice in a patented process, has been found to have a low glycemic index (GI) in a study by IFP Suisse SA. According to the study Policane® has a GI of 51.7+/- 3.66. The study also found that Policane® had a 42% lower GI than white sugar. In its conclusion, the study recommends for Policane® a low glycaemic index product classification under International Standard ISO26642. “We are excited to share the results of this study, providing that Policane® is a low-GI sweetener,” said Jorge Enrique Gonzalez, Manager and CEO at PoliCane Co., LLC. “Policane® retains the best parts of the sugar cane stripped away in refined sugar. Policane® is a natural and sustainable sweetener that the world needs.” Policane® is currently produced under license in Costa Rica and can be used in recipes for all sweetened food and beverages, including baked goods, coffee, tea, colas, sauces, ketchup and desserts. Fo
Nokia Corporation: Repurchase of own shares on 03.10.20233.10.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 3 October 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 03.10.2023 Espoo, Finland – On 3 October 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL344,5423.53CEUX39,5413.54AQEU1,3923.53TQEX14,5253.55Total400,0003.53 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023
Adevinta ASA – Procedures established in response to receipt of non-binding indicative proposal3.10.2023 19:30:00 CEST | Press release
Oslo, 3 October 2023 – Adevinta ASA (“Adevinta” or the “Company”) refers to the stock exchange announcement on 21 September 2023 regarding receipt of a non-binding indicative proposal (the “Proposal”) from a consortium led by Permira and Blackstone, with involvement of the Company’s two main shareholders, regarding a potential offer for all shares of the Company. In response to shareholder enquiries, the Company wants to communicate the procedures it is following in response to the Proposal. Immediately upon receipt of the Proposal, the Company’s board of directors established a special committee comprising the five independent directors on the Company’s board. The special committee is representing the Company in all aspects relating to the Proposal. The directors who are representatives of the three main shareholders of the Company are not involved in the Company’s deliberations and decisions. The independent committee is actively engaging in the Proposal in line with applicable regul